CD8A and colorectal carcinoma: This intervention markedly enhances the antitumor efficacy of CAR-T cells, CD8+ T cells, and mRNA vaccines, offering a promising breakthrough for overcoming resistance in immunotherapy-refractory solid tumors such as MSS CRC.